Barinthus Biotherapeutics (BRNS) Operating Leases (2020 - 2026)

Barinthus Biotherapeutics has reported Operating Leases for 7 years, with the latest figure at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 10.53% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (up 10.53% YoY), and the FY2025 full-year result was $9.3 million, down 8.22% from the prior year.
• Operating Leases for Q1 2026 stood at $11.0 million, up from $9.3 million in the prior quarter.
• The five-year high for Operating Leases was $12.7 million in Q3 2023, with the low at $6.7 million in Q1 2022.
• Historically, Operating Leases has averaged $10.1 million across 5 years, with a median of $10.7 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases soared 500.72% — and 2024, when it retreated 15.9%.
• Barinthus Biotherapeutics' Operating Leases stood at $8.3 million in 2022, then surged by 34.18% to $11.2 million in 2023, then declined by 9.87% to $10.1 million in 2024, then fell by 8.22% to $9.3 million in 2025, then climbed by 18.9% to $11.0 million in 2026.
• The last three Operating Leases figures came in at $11.0 million (Q1 2026), $9.3 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.